



Please Note: Medical Necessity Prior Authorization may be overridden for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

PRIOR AUTHORIZATION **BYPASS**

Juxtapid® (lometapide)

Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs

Name _____

Address _____

R_x atorvastatin 40mg
quantity #
sig: 1 orally 2x/day

as directed by physician

Dx: HYPERCHOLESTER-
OLEMIA E 78.0

MD _____

Signature _____

SAMPLE



Prescriber Information

Last Name: <input type="text"/> DEA/NPI: <input type="text"/> Phone <input type="text"/>	First Name <input type="text"/> Specialty: <input type="text"/> Fax <input type="text"/>
--	--

Member Information

Last Name: <input type="text"/> Member ID Number <input type="text"/>	First Name <input type="text"/> DOB: <input type="text"/>
--	--

Medication Information:

Drug Name and Strength: <input type="text"/> Diagnosis: <input type="text"/>	Quantity and Dosing: <input type="text"/> Duration: <input type="text"/>
---	---

When advised below, please include all requested fax documentation (lab results, etc.) when submitting this Prior Authorization fax form; not submitting requested documentation could delay the clinical review process.

Juxtapid Prior Authorization Form

Initial Therapy		
You must answer ALL of the following questions		
1. Is the patient 18 to 55 years of age?	Y	N
2. Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH)? <i>Please submit copies of initial history and physical OR initial consultation, including (a) clinical course (and, if applicable, documentation of cardiovascular disease before age 20 while patient was untreated) and (b) family history specifically relating to lipid disorders and cardiovascular events.</i>	Y	N
3. Has the patient undergone genetic testing to confirm two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus? <i>Please provide documentation.</i>	Y	N
4. Has the patient undergone cellular testing to demonstrate reduced LDL receptor activity in fibroblasts/lymphocytes equaling 20% or less of the normal activity? <i>Please provide documentation.</i>	Y	N
5. Does the patient have an untreated LDL-C level of greater than 400 mg/dL? <i>Please provide documentation.</i>	Y	N
6. Do both of the patient's parents have an elevated (greater than 250 mg/dL) total cholesterol or LDL-C before lipid-lowering therapy consistent with heterozygous familial hypercholesterolemia? (Please circle)		
<ul style="list-style-type: none"> • Yes • No • LDL levels are not known 		
7. Do both of the patient's parents have a history of early vascular disease (men less than 55 years of age, women less than 60 years of age)?	Y	N



8. Did the patient have cutaneous or tender xanthoma(s) before the age of 10? <i>Please provide documentation.</i>	Y	N
9. Has the patient had a trial and failure of combined therapy using LDL apheresis, high dose statins and cholesterol absorption inhibitors?	Y	N
10. Does the patient have a serum creatinine level from the past 12 months equaling 2.5 mg/dL or less? <i>Documentation required.</i>	Y	N
11. Does the patient have a serum aminotransferase level from the past 12 months equaling less than three times the upper limit of normal? <i>Please submit documentation, along with the normal range listed.</i>	Y	N
12. Does the patient have congestive heart failure?	Y	N
13. Does the patient have a history of cancer within the past 5 years?	Y	N
14. Does the patient have a history of drug or alcohol abuse?	Y	N

Renewal Therapy You must answer ALL of the following questions		
1. Has the patient shown LDL reduction in response to treatment? If yes, please provide supporting documentation (chart notes).	Y	N

Kynamro Prior Authorization Form

Initial Therapy You must answer ALL of the following questions		
1. Is the patient 12 to 53 years of age?	Y	N
2. Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH)? <i>Please submit copies of initial history and physical OR initial consultation, including (a) clinical course (and, if applicable, documentation of cardiovascular disease before age 20 while patient was untreated) and (b) family history specifically relating to lipid disorders and cardiovascular events.</i>	Y	N
3. Has the patient undergone genetic testing to confirm two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus? <i>Please provide documentation.</i>	Y	N
4. Has the patient undergone cellular testing to demonstrate reduced LDL receptor activity in fibroblasts/lymphocytes equaling 20% or less of the normal activity? <i>Please provide documentation.</i>	Y	N
5. Does the patient have an untreated LDL-C level of greater than 400 mg/dL? <i>Please provide documentation.</i>	Y	N
6. Do both of the patient's parents have an elevated (greater than 250 mg/dL) total cholesterol or LDL-C before lipid-lowering therapy consistent with heterozygous familial hypercholesterolemia? (Please circle) <ul style="list-style-type: none"> • Yes • No • LDL levels are not known 		
7. Do both of the patient's parents have a history of early vascular disease (men less than 55 years of age, women less than 60 years of age)?	Y	N
8. Did the patient have cutaneous or tender xanthoma(s) before the age of 10? <i>Please provide documentation.</i>	Y	N
9. Has the patient had a trial and failure of combined therapy using LDL apheresis, high dose statins and cholesterol absorption inhibitors?	Y	N
10. Does the patient have a serum creatinine level from the past 12 months equaling 2.5 mg/dL or less? <i>Documentation required.</i>	Y	N
11. Does the patient have a serum aminotransferase level from the past 12 months equaling less than three times the upper limit of normal? <i>Please submit documentation, along with the normal range listed.</i>	Y	N
12. Does the patient have congestive heart failure?	Y	N
13. Does the patient have a history of cancer within the past 5 years?	Y	N
14. Does the patient have a history of drug or alcohol abuse?	Y	N



Renewal Therapy

You must answer ALL of the following questions

1. Has the patient shown LDL reduction in response to treatment? If yes, please provide supporting documentation (chart notes).	Y	N
---	---	---

Please note, not all drugs/diagnoses are covered on all plans.

Comments: _____
Information given on this form is accurate as of this date.

Prior Authorization forms are located on the Cover Page. Print a new form for each request as forms are updated periodically.

Prescriber or Authorized Signature

Date

Authorized Medical Staff – Name/Title

Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department whose numbers appear on the Cover Page.

I understand that USDoctor's use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996).



Contact Information:

Telephone: (855)251.9116

Fax: (248)593.9575

Please Note: Medical Necessity Prior Authorization may be utilized to override both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

**PRIOR AUTHORIZATION FORM:
COVER PAGE**

MEMBER INFORMATION			
First Name		Last Name	
Plan			
Member ID		Date of Birth	
DRUG INFORMATION			
Drug Name			
Quantity		ICD-10	
Directions		Duration of Therapy	
Diagnosis			
PLEASE LIST ALTERNATIVE THERAPIES THAT HAVE BEEN ATTEMPTED AND ANY OTHER PERTINENT INFORMATION RELATED TO DRUG AND/OR DISEASE STATE. IF NOT PRESENT, WITHIN NORMAL LIMITS WILL BE USED FOR THE REVIEW.			
Medication/Failure Reason:			
IgE: _____			
ESR: _____ CRP: _____ # Joints: _____ %BSA: _____			
Height: _____ Weight: _____ BMI: _____			
HA1C: _____ Hemoglobin: _____ Hematocrit: _____ T-Score: _____			
Dialysis: _____ Long Term Care Facility: _____ Self Injecting: _____			
Stimulation test: _____ / _____ Growth velocity: _____ #Chemotherapy cycles/month: _____			
Mini-Mental Status Test: _____ Baseline Free testosterone/Total testosterone: _____ / _____			
HCV RNA viral load: _____ Viral Genotype: _____ ALT: _____			
PHYSICIAN INFORMATION			
Physician Signature		Date	
Physician Name		NPI #	
Phone Number		Fax Number	
Action Needed	Only mark Urgent when standard review time would seriously harm the member's life or health or ability to regain maximum function <input type="checkbox"/> Urgent <input type="checkbox"/> For Review	Pharmacy Fax	
The information contained in this facsimile message, including the attachments, may be privileged, may constitute inside information and is intended only for use of the addressee. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited and may be unlawful. If you have received this communication in error, please immediately notify me by replying to this message and destroy the original message.			